US7205302 — Heterocyclic compound derivatives and medicines
Method of Use · Assigned to Nippon Shinyaku Co Ltd · Expires 2026-10-31 · 0y remaining
What this patent protects
This patent protects a compound useful as a PGI2 receptor agonist and a pharmaceutical composition containing it.
USPTO Abstract
The present invention provides a compound which is useful as a PGI 2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: (R 1 and R 2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR 5 , O, S, or ethylene, R 5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH 2 , R 3 and R 4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
U-1797 |
— | Uptravi |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.